Clin Lab. 2026 Jun 1;72(3). doi: 10.7754/Clin.Lab.2025.240339.
ABSTRACT
BACKGROUND: This study aimed to investigate the role of serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT) in predicting the occurrence and prognosis of symptomatic cardiovascular toxicities (CVTs) in non-Hodgkin's lymphoma (NHL) patients receiving anthracyclines (ATCs).
METHODS: We conducted a retrospective analysis of serum NT-proBNP and hs-cTnT levels in 182 NHL patients undergoing anthracycline treatment. The post-treatment elevation ratio (ER) of NT-proBNP (NT-proBNP-ER) was calculated, and receiver operating characteristic curves (ROCs) were generated.
RESULTS: The area under the curves (AUCs) of NT-proBNP-ER, hs-cTnT, and their combination for diagnosing symptomatic CVTs were 0.903, 0.811, and 0.9807, respectively. Serum NT-proBNP-ER ≥ 2.56 and hs-cTnT ≥ 11.68 ng/L were positively correlated with the occurrence of symptomatic CVTs. Patients with a post-treatment NT-proBNP-ER ≥ 2.56 had shorter progression-free survival (PFS) and overall survival (OS) than those with an NT-proBNP-ER < 2.56. Similarly, patients with post-treatment hs-cTnT ≥ 11.68 ng/L experienced markedly shorter PFS and OS compared to those with hs-cTnT < 11.68 ng/L.
CONCLUSIONS: An NT-proBNP-ER ≥ 2.56 or hs-cTnT ≥ 11.68 ng/L, individually or combined, are significant predictors of symptomatic CVTs. Exceeding these thresholds indicates a poor prognosis in NHL patients treated with anthracyclines.
PMID:41945746 | DOI:10.7754/Clin.Lab.2025.240339